Six-Month Strategy Holds Up in Rifampicin-Resistant TB
Episode Summary
A randomized South African trial supports six-month treatment for eligible rifampicin-resistant tuberculosis, potentially reducing treatment burden while requiring careful regimen selection and safety monitoring.